VACCINEX ANNOUNCES ANTIBODY COLLABORATION WITH SCHERING

Vaccinex, Inc. has announced that it has entered into research collaboration with Schering AG to identify disease targets and potentially develop therapeutic antibodies for the treatment of certain cancers. Vaccinex will receive a technology access fee and research funding and is eligible for milestone payments and royalties.

Genomics & Proteomics (http://www.genomicsproteomics.com/index.aspx?ID=69437)